Questions about Atrial Fibrillation? Get answers from our expert.

Hydralazine Tablets

Pronunciation

Generic Name: hydralazine hydrochloride
Dosage Form: tablet

Hydralazine Tablets Description

Hydralazine hydrochloride USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is:

C8H8N4• HCl

M.W. 196.64

Hydralazine hydrochloride USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64.

Hydralazine HCl Tablets are available in 10, 25, 50 and 100 mg strengths.

Each tablet contains the following inactive ingredients: lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and stearic acid. In addition, the 10 mg tablet contains FD&C Red #40. The 25 mg, 50 mg and 100 mg tablets contain FD&C Yellow #6.

Hydralazine Tablets - Clinical Pharmacology

Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. Hydralazine, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.

The peripheral vasodilating effect of hydralazine results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. Hydralazine usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption. Hydralazine also maintains or increases renal and cerebral blood flow. Hydralazine hydrochloride is rapidly absorbed after oral administration, and peak plasma levels are reached at 1-2 hours. Plasma levels of apparent hydralazine decline with a half-life of 3-7 hours. Binding to human plasma protein is 87%. Plasma levels of hydralazine vary widely among individuals. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure. Hydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.

Slideshow: 2014 Update: First Time Brand-to-Generic Switches

Indications and Usage for Hydralazine Tablets

Essential hypertension, alone or as an adjunct.

Contraindications

Hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

Warnings

In a few patients hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS,Laboratory Tests.)

GENERAL PRECAUTIONS

Myocardial stimulation produced by hydralazine can cause anginal attacks and ECG changes of myocardial ischemia. The drug has been implicated in the production of myocardial infarction. It must, therefore, be used with caution in patients with suspected coronary artery disease. The “hyperdynamic” circulation caused by hydralazine may accentuate specific cardiovascular inadequacies. For example, hydralazine may increase pulmonary artery pressure in patients with mitral valvular disease. The drug may reduce the pressor responses to epinephrine. Postural hypotension may result from hydralazine but is less common than with ganglionic blocking agents. It should be used with caution in patients with cerebral vascular accidents.

In hypertensive patients with normal kidneys who are treated with hydralazine there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate. In some instances where control values were below normal, improved renal function has been noted after administration of hydralazine. However, as with any antihypertensive agent, hydralazine should be used with caution in patients with advanced renal damage.

Peripheral neuritis, evidenced by paresthesia, numbness, and tingling, has been observed. Published evidence suggests an antipyridoxine effect, and that pyridoxine should be added to the regimen if symptoms develop.

Information for Patients

Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed.

Laboratory Tests

Complete blood counts and antinuclear antibody titer determinations are indicated before and periodically during prolonged therapy with hydralazine even though the patient is asymptomatic. These studies are also indicated if the patient develops arthralgia, fever, chest pain, continued malaise, or other unexplained signs or symptoms.

A positive antinuclear antibody titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with hydralazine.

Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopeia, agranulocytosis, and purpura, have been reported. If such abnormalities develop, therapy should be discontinued.

Drug Interactions

MAO inhibitors should be used with caution in patients receiving hydralazine.

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and hydralazine are used concomitantly.

Food Interactions

Administration of Hydralazine with food results in higher plasma levels.

Carcinogenesis and Mutagenesis and Impairment of Fertility

The extent to which these findings indicate a risk to man is uncertain. While long-term clinical observation has not suggested that human cancer is associated with hydralazine use, epidemiologic studies have so far been insufficient to arrive at any conclusions.

Pregnancy Category C: Animal studies indicate that hydralazine is teratogenic in mice at 20-30 times the maximum daily human dose of 200-300 mg and possibly in rabbits at 10-15 times the maximum daily human dose, but that it is nonteratogenic in rats. Teratogenic effects observed were cleft palate and malformations of facial and cranial bones.

There are no adequate and well-controlled studies in pregnant women. Although clinical experience does not include any positive evidence of adverse effects on the human fetus, hydralazine should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when hydralazine is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in children have not been established in controlled clinical trials, although there is experience with the use of hydralazine in children. The usual recommended oral starting dosage is 0.75 mg/kg of body weight daily in four divided doses. Dosage may be increased gradually over the next 3-4 weeks to a maximum of 7.5 mg/kg or 200 mg daily.

Adverse Reactions

Adverse reactions with hydralazine are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug.

The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.

Common: headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris.

Less Frequent: Digestive: constipation, paralytic ileus.

Cardiovascular: hypotension, paradoxical pressor response, edema.

Respiratory: dyspnea.

Neurologic: peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness, tremors, muscle cramps, psychotic reactions characterized by depression, disorientation or anxiety.

Genitourinary: difficulty in urination.

Hematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly.

Hypersensitive Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis.

Other: nasal congestion, flushing, lacrimation, conjunctivitis.

Overdosage

Acute Toxicity: No deaths due to acute poisoning have been reported. Highest known dose survived: adults, 10 g orally. Oral LD 50in rats: 173 and 187 mg/kg.

Signs and Symptoms: Signs and symptoms of overdosage include hypotension, tachycardia, headache, and generalized skin flushing. Complications can include myocardial ischemia and subsequent myocardial infarction, cardiac arrhythmia, and profound shock.

Treatment: There is no specific antidote.

The gastric contents should be evacuated, taking adequate precautions against aspiration and for protection of the airway. An activated charcoal slurry may be instilled if conditions permit. These manipulations may have to be omitted or carried out after cardiovascular status has been stabilized, since they might precipitate cardiac arrhythmias or increase the depth of shock.

Support of the cardiovascular system is of primary importance. Shock should be treated with plasma expanders. If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate cardiac arrhythmia. Tachycardia responds to beta blockers. Digitalization may be necessary, and renal function should be monitored and supported as required. No experience has been reported with extracorporeal or peritoneal dialysis.

Hydralazine Tablets Dosage and Administration

Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2-4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels.

The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of hydralazine. In a few resistant patients, up to 300 mg of hydralazine daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of hydralazine combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.

How is Hydralazine Tablets Supplied

10 mg - round, light pink colored, unscored tablets, debossed “Par 029” on one side are available in bottles of 100 (NDC #49884-029-01) and 1000 (NDC #49884-029-10).

25 mg - round, peach colored, unscored tablets, debossed “Par 027” on one side are available in bottles of 100 (NDC #49884-027-01) and 1000 (NDC #49884-027-10).

50 mg - round, peach colored, unscored tablets, debossed “Par 028” on one side are available in bottles of 100 (NDC #49884-028-01) and 1000 (NDC #49884-028-10).

100 mg - round, peach colored, unscored tablets, debossed “Par 121” on one side are available in bottles of 100 (NDC #49884-121-01) and 1000 (NDC #49884-121-10).

Store at controlled room temperature 15°-30°C (59°-86°F) [see USP].

Manufactured by:

PAR PHARMACEUTICAL, INC.

Spring Valley, NY 10977

Rev 11/09

OS029-01-1-10

PRINCIPAL DISPLAY PANEL 10MG TABLETS 100’S

PRINCIPAL DISPLAY PANEL 25MG TABLETS 100’S

PRINCIPAL DISPLAY PANEL 50MG TABLETS 100'S

PRINCIPAL DISPLAY PANEL 100MG TABLETS 100'S

HYDRALAZINE HYDROCHLORIDE 
hydralazine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-029
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDRALAZINE HYDROCHLORIDE (HYDRALAZINE) HYDRALAZINE HYDROCHLORIDE 10 mg
Inactive Ingredients
Ingredient Name Strength
LACTOSE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
STEARIC ACID  
FD&C RED NO. 40  
Product Characteristics
Color PINK Score no score
Shape ROUND Size 8mm
Flavor Imprint Code Par;029
Contains         
Packaging
# Item Code Package Description
1 NDC:49884-029-01 100 TABLET in 1 BOTTLE
2 NDC:49884-029-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA087836 10/05/1982
HYDRALAZINE HYDROCHLORIDE 
hydralazine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-027
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDRALAZINE HYDROCHLORIDE (HYDRALAZINE) HYDRALAZINE HYDROCHLORIDE 25 mg
Inactive Ingredients
Ingredient Name Strength
LACTOSE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
STEARIC ACID  
FD&C YELLOW NO. 6  
Product Characteristics
Color ORANGE (Peach) Score no score
Shape ROUND Size 8mm
Flavor Imprint Code Par;027
Contains         
Packaging
# Item Code Package Description
1 NDC:49884-027-01 100 TABLET in 1 BOTTLE
2 NDC:49884-027-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA086961 02/27/1980
HYDRALAZINE HYDROCHLORIDE 
hydralazine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-028
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDRALAZINE HYDROCHLORIDE (HYDRALAZINE) HYDRALAZINE HYDROCHLORIDE 50 mg
Inactive Ingredients
Ingredient Name Strength
LACTOSE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
STEARIC ACID  
FD&C YELLOW NO. 6  
Product Characteristics
Color ORANGE (Peach) Score no score
Shape ROUND Size 9mm
Flavor Imprint Code Par;028
Contains         
Packaging
# Item Code Package Description
1 NDC:49884-028-01 100 TABLET in 1 BOTTLE
2 NDC:49884-028-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA086962 02/27/1980
HYDRALAZINE HYDROCHLORIDE 
hydralazine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-121
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDRALAZINE HYDROCHLORIDE (HYDRALAZINE) HYDRALAZINE HYDROCHLORIDE 100 mg
Inactive Ingredients
Ingredient Name Strength
LACTOSE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
STEARIC ACID  
FD&C YELLOW NO. 6  
Product Characteristics
Color ORANGE (Peach) Score no score
Shape ROUND Size 11mm
Flavor Imprint Code Par;121
Contains         
Packaging
# Item Code Package Description
1 NDC:49884-121-01 100 TABLET in 1 BOTTLE
2 NDC:49884-121-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA088391 09/27/1983
Labeler - Par Pharmaceutical, Inc. (092733690)
Registrant - Par Pharmaceutical, Inc. (092733690)
Establishment
Name Address ID/FEI Operations
Par Pharmaceutical Inc. 092733690 MANUFACTURE(49884-029, 49884-027, 49884-028, 49884-121)
Establishment
Name Address ID/FEI Operations
Par Formulations Pvt. Ltd. 676159161 MANUFACTURE(49884-029, 49884-027, 49884-028, 49884-121)
Revised: 06/2014
 
Par Pharmaceutical, Inc.
Hide
(web4)